9 results about "Repair enzyme" patented technology

A method of selecting a treatment for a subject having cancer is disclosed. The method comprises:(a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and(b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of the DNA repair enzyme as compared to the catalytic activity of the DNA repair enzyme in a biological sample of a healthy subject.

The application relates to the field of second-generation sequencing, in particular to an ultrahigh-throughput multiplex PCR amplicon capture method for second-generation sequencing. The NGS capture method comprises the following steps: 1) performing multiplex PCR amplification on a sample to be detected by using a digestible composite modified primer pair, to obtain a PCR product; 2) performing an enzyme cutting reaction on the PCR product by using a second enzyme mixture containing a primer digestion enzyme, a mismatch correction enzyme and a terminal repair enzyme, including removing the excess primer part on the amplification product by using the digestion enzyme, and removing the non-specific amplification product by using the mismatch correction enzyme; 3) performing a ligation reaction by using a full-length adapter containing an index, to directly obtain a sequencing library or obtain a sequencing library after amplification. The method significantly improves the amplification efficiency and specificity, and has the advantages of simple steps, low cost, short time, wide application value in the fields of genetic disease detection, tumor companion diagnosis and genetic detection and scientific research.

The invention provides a dual-targeting nano-material photosensitizer for cervical cancer as well as a preparation method and application of the dual-targeting nano-material photosensitizer. The folic acid modified poly-beta-cyclodextrin (poly-beta-CD) is used as a nano-carrier and is used for loading a photosensitizer PAP (PAP is pyropheophorbide a covalently connected PAAKRVKLD) coupled with a nuclear localization signal (NLSs). The finally prepared FA-CD-coated PAP nano material can specifically recognize cervical cancer cells of overexpressed folate receptors (FR), so that accumulation in tumor cells is remarkably enhanced. In addition, the encapsulated PAP can achieve accurate cell nucleus localization. Under an illumination condition, reactive oxygen species (ROS) generated by PAP accumulated in nuclei can instantly oxidize and damage a DNA chain or DNA repair enzyme, so that cell death is directly induced, and the anti-tumor effect of targeted photodynamic is greatly enhanced. The novel dual-targeting nano drug-loading system prepared by the invention solves the problems of poor targeting and biological solubility and limited treatment effect of a traditional photosensitizer, and provides an innovative intelligent targeting delivery strategy for in-situ cell nucleus photodynamic therapy.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

The invention provides a construction method for simultaneously expressing 6-4 photolyase and 8-HDF synthetase in bacillus subtilis. According to the invention, bacillus subtilis is used as an expression host, and codons of a photolyase PhoB gene and an 8-HDP synthetase ScFbiC gene are optimized. The optimized gene sequences respectively correspond to SEQ ID NO: 1 and SEQ ID NO: 2. According to the invention, two gene segments are connected with a vector pP43NMK, plasmids NMK-P43-PhoB and NMK-P43-ScFbiC are constructed, tandem expression of PhoB and ScFbiC is realized, and the plasmids NMK-P43-PhoB-Pyvyd-ScFbiC are further constructed. The plasmid is transformed into a bacillus subtilis WB600 cell, and the genetically engineered bacterium NMK-P43-PhoB-Pyvyd-ScFbiC is successfully constructed, so that the genetically engineered bacterium NMK-P43-PhoB-Pyvyd-ScFbiC is obtained. The constructed bacillus subtilis 6-4 photolyase expression system has the application potential in the field of cosmetics.

The invention discloses a preparation method of a spherical DNA nano machine for detecting O6-methylguanine-DNA methyltransferase (MGMT) and application of the spherical DNA nano machine in detection of the expression level of tumor cells MGMT. The method comprises the following steps: firstly, designing a DNA walker with MGMT recognition and signal amplification functions, and fixing the DNA walker on the surface of a gold nanosphere through sulfydryl modification to construct a spherical DNA nanomachine; when the MGMT interacts with a DNA Walker chain, a methylated basic group G on DNA enzyme can be repaired, so that the activity of the DNA enzyme is recovered, an enzyme digestion reaction is initiated, a Track chain marked with a fluorophore is broken and released, a fluorescence signal change is generated, and high-sensitivity detection of the MGMT is realized. The method can effectively detect the MGMT protein in a low concentration range, and has a good biomedical application prospect.

The invention relates to the technical field of polysaccharide compound extraction and application, in particular to a method for extracting tremella polysaccharide from tremella and freckle-removing and whitening light repairing enzyme applied to the method. The invention discloses a method for extracting tremella polysaccharide from tremella fuciformis, which comprises the following steps: firstly, mixing tremella fuciformis powder with a buffer solution, adding immobilized compound enzyme for enzymolysis, and then recovering the enzyme; extracting, cooling and filtering the enzymatic hydrolysate; adding alkaline protease into the filtrate for deproteinization, adding activated carbon for decoloring and concentrating; finally, trehalose and silicon dioxide are added into the concentrated solution, and tremella polysaccharide is obtained through spray drying. Wherein the immobilized compound enzyme is prepared by immobilizing a mixed enzyme by composite microspheres in a specific ratio, and the composite microspheres are prepared by the steps of carrier modification, crosslinking and the like. The preparation method comprises the following steps: compounding polysaccharide with superoxide dismutase and glutathione reductase, dissolving, activating, mixing and the like to obtain the freckle-removing and whitening light repairing enzyme.

Compositions for skin creams and serums are provided for treating skin hyperpigmentation, the compositions including cysteamine, tranexamic acid, niacinamide, tetrapeptide 30, DNA repair enzymes, and human growth factors. A formulation for the skin cream or serum includes 5% cysteamine by weight, 5% tranexamic acid by weight, 4% niacinamide by weight, 1% tetrapeptide 30 by weight, in which the tetrapeptide 30 includes the following four amino acids linked together: L-prolyl-L-lysyl-L-alpha-glutamyl-L-lysine. In addition, the cream or serum includes DNA repair enzymes, including 1% phytosomes, 0.3 to 1% roxisomes, and 1% ultrasomes. Further, the composition may include recombinant human growth factors.

Malignant glioma has a poor prognosis, despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant cycles of TMZ. O6-methylguanine DNA methyltransferase (MGMT) is a DNA repair enzyme which removes alkylated lesions from tumor DNA, thereby promoting chemoresistance. MGMT promoter methylation is a known predictor of temozolomide responsiveness; patients with unmethylated MGMT have a poorer prognosis. We employed deactivated Cas9-CRISPR technology to effectively target methylation in the vicinity of the MGMT methylation-specific polymerase chain reaction (MSP) region, as mediated by the catalytic domain of DNA methyltransferase DNMT3A. In doing so, we discovered that the selected dCas9 / CRISPR-mediated methylation of certain regions of MGMT gene sequences can be used to enhance chemosensitivity in malignant glioma cells.